Lobe Sciences Ltd. News Releases

Lobe Sciences Announces Additional Details Regarding the Acquisition of Altemia(TM) & Company

Fri, 30 Jun 2023 22:03:00 -0400

Move Affirms Lobe's Position as an Orphan/Rare Disease Drug Development Company and expands portfolio to include 4 Orphan Disease Programs The Company expects to Launch Altemia™, a Medical Food, and Generate Commercial Revenue in the Second Half of 2023Acquisition also Includes an International License Agreement With Double Digit Royalty and Milestone Payments and Commercial Inventory and Intellectual Property.Vancouver, British Columbia--(Newsfile Corp. - June 30, 2023) - Lobe Sciences Ltd....

Lobe Sciences, Ltd. Provides Update on Vitamind

Fri, 21 Apr 2023 17:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - April 21, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today provides an update on its acquisition of the Vitamind Brand and intellectual property ("Vitamind") pursuant to an asset purchase agreement dated April 30, 2021 (the "Agreement"). Pursuant to the Agreement, the Company...

Lobe Sciences, Ltd. Announces the Acquisition of Altemia(TM) & Company

Tue, 18 Apr 2023 08:58:00 -0400

Move Affirms Lobe's Position as an Orphan/Rare Disease Drug Development Company and expands portfolio to include 4 Orphan Disease Programs The Company expects to Launch Altemia™, a Medical Food, and Generate Commercial Revenue in the Second Half of 2023Acquisition also Includes an International License Agreement With Double Digit Royalty and Milestone Payments, Commercial Inventory and Intellectual Property.Vancouver, British Columbia--(Newsfile Corp. - April 18, 2023) - Lobe Sciences Ltd. (CSE:...

Lobe Sciences to Present at Sequire Cannabis & Psychedelics Conference April 5, 2023

Tue, 04 Apr 2023 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") a North American Biopharmaceutical company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today announced that Philip Young, CEO and Executive Chairman, will present at the SEQUIRE CANNABIS & PSYCHEDELICS CONFERENCE, April 5th at 10:00AM EDT.Registration for the event is accessible via the following link Sign up...

Lobe Sciences Ltd. Announces That The Drug Enforcement Administration Has Issued The Initial 2023 Quota Allowing Export Of L-130

Wed, 22 Mar 2023 09:01:00 -0400

Dosing In Human Clinical Trial To Commence Within Weeks Vancouver, British Columbia--(Newsfile Corp. - March 22, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today announced that its exclusive commercial manufacturing partner has received their initial 2023 quota for our novel psilocin drug product (L-130) from the Drug...